Modality
mAb
MOA
IL-23i
Target
SMN2
Pathway
Apoptosis
GIST
Development Pipeline
Preclinical
~Jan 2014
→ ~Apr 2015
Phase 1
~Jul 2015
→ ~Oct 2016
Phase 2
Jan 2017
→ Mar 2028
Phase 2Current
NCT05652330
362 pts·GIST
2017-04→2026-01·Active
NCT07353906
2,054 pts·GIST
2017-01→2028-03·Completed
2,416 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-01-192mo agoPh3 Readout· GIST
2028-03-162.0y awayPh3 Readout· GIST
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P2/3
Complet…
P2/3
Active
Catalysts
Ph3 Readout
2026-01-19 · 2mo ago
GIST
Ph3 Readout
2028-03-16 · 2.0y away
GIST
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05652330 | Phase 2/3 | GIST | Active | 362 | CfB |
| NCT07353906 | Phase 2/3 | GIST | Completed | 2054 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 | |
| Bemasotorasib | Exelixis | Phase 2 | CD38 | |
| Tirasotorasib | Viking Therapeutics | Phase 1 | CFTR | |
| Olpafutibatinib | Immunocore | Approved | SMN2 |